Literature DB >> 14758567

Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas.

C Onofri1, A Carbia Nagashima, L Schaaf, M Feirer, P Lohrer, W Stummer, S Berner, A Chervin, V Goldberg, G K Stalla, U Renner, E Arzt.   

Abstract

Estrogens are considered to be critically involved in lactotroph and lactosomatotroph pituitary tumor development. In addition to direct effects, estradiol-induced tumor formation may involve alterations in growth factor and cytokine production. We have studied whether estradiol stimulates the production of the angiogenic vascular endothelial growth factor and the potential tumor progression factor interleukin-6 in 5 lactotroph (LA) and 5 lactosomatotroph (LSA) human pituitary adenoma cell cultures. All tumors secreted heterogenous basal amounts of VEGF (18.0 +/- 1.4 to 425 +/- 26 pg/ml per 24 h) and IL-6 (18.1 +/- 1.5 to 604 +/- 17 pg/ml per 24 h). Estradiol (100 nM) significantly enhanced VEGF release in all LA and LSA cell cultures (47 to 168 % above basal). IL-6 secretion was stimulated in 3 out of 5 LA and in all LSA cell cultures (31 to 287 % above basal). In cell cultures obtained from tumors from which sufficient cells could be isolated, a dose-dependent effect of estradiol (1 to 100 nM) on VEGF and IL-6 production was observed. Stimulation of IL-6 and/or VEGF secretion by estradiol in the majority of human lactotroph and lactosomatotroph adenoma cell cultures studied, suggests that estrogens may contribute to adenoma expansion through the stimulation of these auto-/paracrine-acting adenoma progression factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14758567     DOI: 10.1055/s-2004-815722

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Subcellular localisation of VEGF in different pituitary cells. Changes of its expression in oestrogen induced prolactinomas.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Silvina Gutiérrez; Félix Daniel Roth; Agustín Aoki; Alicia Inés Torres
Journal:  J Mol Histol       Date:  2006-05-19       Impact factor: 2.611

Review 2.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

3.  Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Teresa Gagliano; Carlo Filieri; Mariella Minoia; Mattia Buratto; Federico Tagliati; Maria Rosaria Ambrosio; Marcello Lapparelli; Matteo Zoli; Giorgio Frank; Ettore degli Uberti; Maria Chiara Zatelli
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

4.  Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.

Authors:  Katsuhiro Miyajima; Susumu Takekoshi; Johbu Itoh; Kochi Kakimoto; Takashi Miyakoshi; Robert Yoshiyuki Osamura
Journal:  Acta Histochem Cytochem       Date:  2010-04-07       Impact factor: 1.938

5.  Lactotrophs: the new and major source for VEGF secretion and the influence of ECM on rat pituitary function in vitro.

Authors:  Joachim Alfer; Joseph Neulen; Andreas Gaumann
Journal:  Oncol Rep       Date:  2015-03-13       Impact factor: 3.906

Review 6.  Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.

Authors:  Carolina Cristina; Guillermina María Luque; Gianina Demarchi; Felicitas Lopez Vicchi; Lautaro Zubeldia-Brenner; Maria Ines Perez Millan; Sofia Perrone; Ana Maria Ornstein; Isabel M Lacau-Mengido; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Int J Endocrinol       Date:  2014-11-18       Impact factor: 3.257

Review 7.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.